Local delivery system comprising two aerosol chambers

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, and can be used in need of the delivery of therapeutic compositions for local application, including for local analgesic therapy. That is ensured by a system comprising a container having a first chamber with a therapeutic composition for local application with at least one active ingredient, and a second chamber containing a coating composition. The composition for local application and the coating composition is dispensed through a valve and supplied through one nozzle gradually. The delivery can be also gradual by dispensing the composition for local application by pressing a first release button, while the coating composition is dispensed from the system by pressing a second release button.

EFFECT: invention provides the most convenient delivery of the therapeutic compositions ensured by the gradual release of the two compositions having different consistence through the same nozzle.

22 cl

 

Background of invention

Therapeutic compositions for topical application are traditionally used to relieve pain in muscles and joints, as well as the irritation and inflammation of the skin. In recent years, traditional active ingredients for topical application, such as menthol, began to be used to treat other types of pain, particularly headache. These products come in the form of pencils and creams for application to the scalp, despite the fact that menthol is a traditional tool for local application in the treatment of pain in muscles and joints. These methods of treatment suggests that the pain people are extremely diverse, and its sources, mechanisms and methods of treatment are not fully understood by health professionals and consumers painkillers.

The efficacy of therapeutic drugs for local application can be improved by fixing the drug or active ingredient on the skin surface. In this case, this fixation has several advantages, including the retention of volatile components, preventing Erasure therapeutic compositions for topical application to the skin surface, for example, clothing as well as sealing components of therapeutic product for local use, have their unpleasant smell. Fixing therapeutic compositions for topical application can also be used for more active introduction of component local action due to being placed on it, a constant pressure through the epithelial layer of the skin. Fixing, for example, by coating applied in therapeutic compositions for topical application of the patch, could also improve the action of active components due to the higher permeability of the skin under the patch. To optimize fixation on the skin surface can be used a variety of tools, including headbands, fabric, layers of hydrophobic liquid, tape, wetting patch medication for local application.

Fabric applied by spraying, are a new technology and enable you to spray the fibrous material on the surface of the body or substrate with the formation of temporal layers or coatings, reminiscent of the fabric. They are generally called non-woven materials of the type which, in particular described in application for U.S. patent No. 2005/0222320, which refers to the sprayed fabric consisting of fibers, binder and diluent. The sprayed fabric may contain components with therapeutic or sensitizing effects; such as the local warming or heating. When the inclusion of such funds in the composition of the sprayed fabric which is stuck in its matrix structure, which limits its selection to the surface of the skin or subsequent absorption through the skin into the underlying tissue. In addition, if the tool is impregnated with the sprayed fabric, it must be compatible with the sprayed composition (that is, polymers, fibers, solvents, spray and binders)to the active ingredient did not break the functionality of the tissue. If the active ingredient impregnated fabric, the active ingredient after application actually is not fixed and, therefore, can be wiped off clothing and other surfaces, and can also emit an unpleasant odor.

In the field of the known device dual dispensing liquids, which provide dispensing of various liquids, including simultaneous dispensing of multiple fluids. In U.S. patent No. 4969579 two fluids are mixed with the simultaneous dispensing of two-chamber container. In U.S. patent No. 5535950 reported for dispensing two liquids from dual piston syringe, you can use one shared starter.

Many traditional painkillers compositions for topical application contain one or more revulsive funds as active components. Revulsive means of create a sensation of cold, warmth, tingling and other sensations, which, as it is read, prevent the transmission of pain signals to the brain, providing temporary weakening of the perception of pain in the muscles or joints. For example, an anesthetic cream Ben Gay Ultra Strength contains such active repulsive components like menthol (10%), camphor (4%) of methylsalicylate (30%), and begins to exert a sensitizing effect for approximately 3 minutes, which lasts approximately 90 minutes.

The cooling means described in the field as drugs to stimulate sensations, for example, in U.S. patent No. 7189760, which describes essentially a pure compound and method for producing ethyl ether complex N-[[5-methyl-2-(1-methylethyl)cyclohexyl]carbonyl]glycine. According to the description, this material has a very high physiological cooling activity.

Similarly describes other cooling agents in U.S. patent No. 7030273. In the mentioned patent demonstrated that N-alkoxyalkane 2,3-dimethyl-2-isopropylpyrimidine compounds have a physiological cooling effect.

The invention described herein can be used to improve delivery of therapeutic agents for local use and to avoid incompatibility issues associated with the impregnation of the fabric.

Brief description of the invention

The present invention described in this application is a SPO is on and the device anesthetic composition for topical application, delivered with the tools that are convenient and provide fixation of the composition. In the present invention fixation provide the sprayed polymer sprayed polymer complex or sprayed fabric. In one embodiment, the invention presents a method to improve the validity, effectiveness and stability of funds for local use due to fixation using spray fabric or polymeric complex.

In addition, when implementing the present invention will be realized and other benefits, including: application of medicines for local use without the oily and fatty substances, therapeutic compositions for topical application, because it is not erased by the external surfaces (i.e. clothing); prevent the allocation of an unpleasant smell, which can be typical for some painkillers local action; targeted delivery of drugs for local use.

In one embodiment, the invention is a therapeutic composition for topical application delivered from a single chamber multi-chamber containers, and after that on top of the product for local use is distributed sprayed fabric or polymeric complex of separate chambers under pressure in the same capacity.

The advantage of zaklyuche the Xia is that individual components of a therapeutic agent and covering the composition provides increased stability and less interact with each other during storage, which simplifies the selection of the composition of the mixture and increases the shelf life of the drug.

In one aspect of the invention, the atomizing device provides applying to the skin a therapeutic agent, which is covered and protected with a conformal protective coating, forming a medicinal patch. The application of medicinal plaster coating allows you to get the patch that can be applied on any part of the body and which is well stick even in bending and stretching of the skin, such as on the elbows and knees. Covering component tape being substantially inert, provides protection underneath therapeutic compositions for topical application.

Detailed description of the invention

The first part of the present invention includes the distribution of therapeutic compositions for topical application of the spray device; and therapeutic composition for topical application has the form of liquids, suspensions, creams, emulsions or ointments. Therapeutic agent for topical application is distributed from different devices depending on the form of media, including manual spray of bullets is erestor or spray under pressure, as in the case of liquid. In one of the embodiments of the invention, the spray can be applied through the chamber of a spray under pressure, which also contains the spray substance.

In one embodiment of the invention, where the product for local use is a viscous suspension, cream or emulsion, you can use a hand pump to dispense a fixed amount of a therapeutic agent for local use one or a few clicks of the lever of the pump. Since the distribution of therapeutic drugs for local application and the sprayed fabric is done sequentially dispensing drugs for local application and sprayed tissue can be performed with a common lever or button. In this embodiment of the invention a partial push of a lever or button the pump first leads to the dosing of a therapeutic agent for topical application to the desired area of the skin, after which the lever of the pump physically stop, and further pressing of the lever of the pump leads to dosing sprayed fabric on top medicines for local use.

In this application, the term "therapeutic composition for topical application" means a composition that is distributed on the skin and is designed to relieve irritation or b is whether at some time. Such compositions may include compounds using warming of the active component or components, encouraging sensitivity, cooling active ingredients or components that stimulate the sensitivity of the components, causing numbness or tingling, revulsive funds or analgesics local action.

"Covering the song" in this application is called composition, which is applied after the distribution of therapeutic compositions for topical application and which seals therapeutic composition for topical application on the skin.

In this application, the term "sequential delivery" means the delivery method, in which the first predetermined area of skin of the patient is applied therapeutic composition for topical application, containing the drug, and then put a cover song on top of a therapeutic composition for topical use.

The description of the device for dosing

Therapeutic composition for topical application and sprayed the fabric can be placed in containers and packages of various configurations, allowing you to consistently apply two components.

In one embodiment, a device for spraying the first component and the second component is injected into the surface the skin through two separate holes, managed manually using two separate buttons or producing levers. In this embodiment, the first invention can be applied to the local destination through one of the holes and using a single button or releasing the lever, and the application covering the composition (i.e. the sprayed fabric) is then performed manually by using the second button or allow the lever. In this embodiment of the invention, the consumer causes these components to the skin in accordance with the attached to the product instructions. The consumer or the patient at its discretion, use a therapeutic composition for topical application as adding a covering composition, so without it.

In the embodiment providing two holes for dispensing two compositions, text instructions can also be accompanied by images illustrating the sequence of application components. Such statements may relate, in particular, the vertical location of the two outlet openings of the pump, in which the hole for the preparation of local action is higher or lower than the opening for covering the song. Other methods include varying the size of the buttons pumps, exhaust levers or outlets, including the variation of the height, length or width. Two hole is, button pump or the exhaust arm can be color or digital marking, where a therapeutic composition for topical application indicated with the label "1" or "+", and covering the composition indicated with the label "2" or "++". In the present embodiment of the invention the device includes a first chamber containing a therapeutic composition for topical application, and the second chamber containing the covering composition; and each camera has a separate outlet. Two cameras are combined into a single device for dosing.

In one of the embodiments of the invention, the delivery device includes a first chamber containing a therapeutic composition for topical application, and the second chamber containing the covering composition, and the contents of the two cameras distributed on the skin turns through one hole with a single button of a spray. In this embodiment of the invention in the outlet of the integrated control valve sequential delivery. In this embodiment of the invention by pressing the discharge button, lever or the guide nozzle is allocated a certain dose of a therapeutic composition for topical application, and behind it - a certain dose covering composition. In one of the embodiments invented the I such sequential delivery is performed through a valve or separator, allows you to apply the product from one of the holes one by clicking on the button or lever. In one of the embodiments of the invention provides dual separate hole through which the consistent delivery of therapeutic compositions for topical application is performed by clicking on the discharge lever. In one of the embodiments of the invention the device has a valve of a pending dosing, working from the spring of the clock mechanism. Other ways of entering therapeutic compositions for topical application and coating compositions is the use of a flapper valve, which is driven by the pressure, and the pressure in the dosing of a therapeutic composition for topical application differs from the pressure in the covering composition, and differential pressure activated valve.

In one of the embodiments of the invention, the delivery device has a first chamber containing a therapeutic composition for topical application, and the second chamber containing the covering composition; and two compositions are distributed on the skin sequentially through two separate holes with a single button of the spray, which controls the sequential operation of both holes, and (i) a therapeutic composition for topical application distribution is aetsa first, and then on top of a therapeutic composition for topical application is distributed covering composition; or (ii) application covering the composition occurs with a delay after the start of application of therapeutic composition for topical application, which still continues; or (iii) application covering the composition begins simultaneously with the application of therapeutic compositions for topical application. In case (ii) or (iii) in order to cover the song have already been covered therapeutic composition for topical application, the spray openings directed to those areas that are close to each other, but separately, and when moving the system application on the skin of a therapeutic composition for topical application is distributed first, and covering the composition is at least partially distributed over therapeutic compositions for topical application.

In one variant of the invention, therapeutic compositions for topical application are applied using a hand pump. In a separate embodiment, the invention is a therapeutic composition for topical application is distributed manually by pressing the lever, dispenser, and covering the composition is distributed compressed spray agent. In another embodiment of the invention about the camera contain compressed spray agents. In a separate embodiment, the invention provides a third chamber with pressurized spray agent, which is used for dispensing as therapeutic compositions for topical application, and cover songs.

Among the spray agents suitable for use in the present invention include, among others, a mixture of volatile hydrocarbons such as propane, n-butane and isobutane; dimethyl ether (DME), metaliteracy ether; nitrous oxide, carbon dioxide, hydrofluroalkane (HFA): HFA 134a (1,1,1,2,-Tetrafluoroethane) or HFA 227 (1,1,1,2,3,3,3-Heptafluoropropane), and mixtures thereof.

External aerosol container has one or more chambers or sections. The camera can be made of different materials, including, among others, steel, tin, aluminum, copper, polypropylene, polyethylene or combinations thereof or alloys. If you use compressed sprayed covering composition, a device for dispensing has a hole, activator, gasket, spring and immersion tube is lowered into the camera with the cover composition.

Description therapeutic compositions for topical use

Therapeutic compositions for topical use that are the subject of the present invention, can be prepared in various forms for application (local application) on the patient's skin. For example, what the song can be applied in the form of a gel, cream, ointment, liquid, sprayable liquid composition for application by brush, solidified emulsion or cream (i.e. face masks), aerosol, powder, oil, balm, ointment or adhesive bandages. Therapeutic compositions for topical use that are the subject of the present invention may take the form of a fusible solids, semi-solid substances, solutions, suspensions or emulsions. In addition, the composition can be impregnated bandage, hydrocolloid dressing, a bandage or cloth. In one of the embodiments of the invention, a therapeutic composition for topical application can be moisture resistant and not be washed off from the skin.

Among the suitable external analgesics include, among others, analgesics, described in the Tentative Final Monograph for External Analgesic Drug Products for over-the-counter human use (Tentative final monograph for external analgesics sold to consumers without a prescription), U.S. Federal Register Vol. 48, No. 27, Feb 28, 1983. Specified in the Pharmacopoeia articles external analgesics contain revulsive means, causing redness, for example, allylisothiocyanate 0.5 to 5%, methyl salicylate 10-60% and turpentine oil 6-50%; irritant, causing cooling, for example, camphor >3% to 11% or menthol 1,25-16%; irritant, causing dilation of blood vessels, for example, histamine dihydrochloride 0,025-010% or methylnicotinate 0.25 to 1%; and irritant, do not cause redness, for example, capsaicin 0,025-0,25%, Cayenne pepper containing capsaicin 0,025-0,25% or essential oil Cayenne pepper containing capsaicin 0,025-0,25%.

To appropriate funds from itching include corticosteroids, such as, among others, hydrocortisone and fordread and remedies based on herbs, such as, among others, chamomile, tea tree oil and calendula. To antihistamines local action, suitable for use in therapeutic compositions include, in particular, doxepin. In one variant of the invention, therapeutic composition contains an anesthetic active ingredient and a remedy for itching. In another embodiment of the invention, therapeutic composition comprises a first anesthetic active ingredient, and the cover composition contains the remedy for itching.

Appropriate cooling means, stimulating sensitivity, are not included in the monograph, are selected from the group which includes, in particular, [ (-)-isopulegol, (2S)-3-(l-methoxy)propane-1,2-diol, Frescolat MGA/entepicondylar, Frescolat ML/Mantellate, WS-14/N-tert-butyl-para-Menten-3-carboxamide, WS-23/2-isopropyl-N,2,3-trimethylbutyramide, WS-12/N-(4-methoxyphenyl)-para-Menten-3-carboxamide, WS-3/N-ethyl-para-Menten-3-carboxamide and WS-5/ethyl 3-(para-Menten-carboxamido)acetate].

In other embodiments the invention, therapeutic compositions for topical application may also contain drugs transdermal delivery, including, among others, analgesics, anti-infective tools, heart drugs, antidepressants, hormonal supplements and medications for addiction treatment, in particular, from nicotine and nicotine analogs, drugs to treat Central nervous system, drugs for diabetes or any other drugs or active substances for the treatment of diseases or mitigate symptoms of diseases or conditions of the patient. In another embodiment of the invention including painkillers include, in particular, Ketoprofen, ibuprofen, diclofenac, niflumova acid, felbinac and piroxicam.

In other embodiments the invention, therapeutic compositions for topical application may also contain a means of facilitating penetration, which increase the permeability of skin to drugs or active ingredients contained in therapeutic compositions for topical application.

In certain embodiments the invention, therapeutic compositions for topical use that are the subject of the present invention, contain de is motologichesky acceptable carrier. This carrier should be suitable for local use, that is, to be compatible with the active components described herein. Safe and effective amount of the carrier ranges from about 50% to about 99% by weight of the compositions that are the subject of the present invention, preferably from about 75% to about 99% by weight of these compositions, and most preferably from about 75% to about 95% by weight of these compositions.

Therapeutic compositions for topical application, which can be used in the framework of the present invention may take the form of solutions. The solutions usually contain water or an organic solvent (for example, from about 50% to about 99.99 percent, or from about 90% to about 99% of a cosmetically acceptable aqueous or organic solvent). Examples of appropriate organic solvents include: propylene glycol, polyethylene glycol (200-600), polypropylenglycol (425-2025), glycerol, 1,2,4-butanetriol, esters of sorbitol, 1,2,6-hexanetriol, ethanol and mixtures thereof.

Therapeutic compositions for topical application, which can be used for the purposes of the present invention, can be prepared in the form of a solution containing emollient. Such compositions, the pre is respectfully, contain from about 2% to about 50% softener(s). The term "softeners" in this document are the materials used to prevent or reduce dryness and protect the skin. There are a large number of different softeners suitable for use within the present invention. In the publication Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972), and the dictionary-directory International Cosmetic Ingredient Dictionary and Handbook, eds. Wenninger and McEwen, pp. 1656-61, 1626, and 1654-55 (The Cosmetic, Toiletry, and Fragrance Assoc., Washington, D.C., 7th Edition, 1997) (hereinafter "ICI Handbook") contains numerous examples of acceptable materials.

From a solution containing a softener may be made lotion. Lotions typically comprise from about 1% to about 20% (e.g. from about 5% to about 10%) of the softener(s) and from about 50% to about 90% (e.g., from about 60% to about 80%) of water. Another type of product that can be produced from a solution containing a softener, is cream. The cream usually contains from about 5% to about 50% (e.g., from about 10% to about 20%) of the softener(s) and from about 45% to about 85% (e.g., from approximately 50% to approximately 75%) is water.

Another type of product that can be made is atollen from the solution, containing the softener is ointment. The ointment may contain simple basis of animal or vegetable oils or semi-solid hydrocarbons. The ointment may contain from about 2% to about 10% softener(s), plus from about 0.1% to about 2% of a thickening agent(s). A more complete description of the thickening agent or agents for increasing the viscosity, which can be used in this invention can be found in the publication Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 72-73 (1972), and in the ICI Handbook Handbook pp. 1693-1697.

Therapeutic compositions for topical application, which can be used in the framework of the present invention can be in the form of emulsions. If the carrier is an emulsion, it is about 1%-10% (for example, approximately 2%-5%) consists of emulsifier(s). The emulsifiers can be nonionic, anionic or cationic. Appropriate emulsifiers are described, for example, in U.S. patent No. 3755560, 4421769, McCutcheon's Detergents and Emulsifiers, North American Edition, pp. 317-324 (1986) and in the directory ICI Handbook, pp.1673-1686.

Lotions and creams can be made in the form of emulsions. Typically such lotions comprise from about 0.5% to about 5% emulsifier(s). These creams usually contain from about 1% to about 20% (e.g. from about 5% to about 10%) of the softener(s); of the approximately 20% to approximately 80% (for example, from 30% to approximately 70%water; and from about 1% to about 10% (e.g. from about 2% to about 5%) emulsifier(s).

Preparations for skin care on the basis of unilateral emulsions, such as lotions and creams of type oil-in-water and water-in-oil, well known in the cosmetic industry and can be used within the present invention. Multiphase emulsion compositions, such as compositions of the type water-in-oil-in-water"described in U.S. patent No. 4254105 and 4960764, can also be used within the present invention. In General, such a one-sided or multi-phase emulsion containing as a mandatory component water softeners and emulsifiers.

Therapeutic compositions for topical use that are the subject of the present invention may also take the form of a gel (e.g., aqueous, alcoholic, aqueous-alcoholic or oily gel using a valid(s) gelling(their) agent(s)). Valid gelling agents for aqueous and/or aqueous-alcoholic gels include, but is not limited to, natural gums, acrylic acid, acrylate polymers and copolymers, cellulose derivatives (for example, hydroxymethylcellulose and hydroxypropylcellulose). Valid gelling agents for oils (e.g. mineral oil) apply, including the guide is generowanie copolymer of butylene, ethylene and styrene and hydrogenerating copolymer of ethylene, propylene and styrene. In these gels, the content of the gelling agent generally ranges from about 0.1% to 5% by mass.

Therapeutic compositions for topical use that are the subject of the present invention may also take the form of solid compositions (e.g., pencil-based wax, bar soap, or detergent wipes with powder).

Liposomal formulations are also useful compounds from the point of view of the present invention. Examples of liposomes can be unilamellar, multilamellar and oligomineralnye liposomes, which may contain or not contain phospholipids. Such compositions can be obtained by first mixing hesperetin with a phospholipid, such as dipalmitoylphosphatidylcholine, cholesterol and water according to the method described in the publication Mezei & Gulasekharam, Liposomes-A Selective Drug Delivery System for the Topical Route of Administration; Gel Dosage Form, Journal of Pharmaceutics and Pharmacology, Vol. 34 (1982), pp. 473-474, or modifications of them. The lipids of the epidermal layer with a composition suitable for forming liposomes, could be replaced by phospholipids. Then liposomal preparation can be embedded into one of the above carriers (i.e. gel or emulsion of the oil-in-water) to obtain the liposomal composition. Other liposomal drugs for local use, and how is their use are described in publications Mezei, M., Liposomes as a Skin Drug Delivery System, Topics in Pharmaceutical Sciences (D. Breimer and P. Speiser), Elsevier Science Publishers B. V., New York, N.Y., 1985, pp. 345-358, the patent application PCT No. WO96/31194, Niemiec, et al., 12 Pharm. Res. 1184-88 (1995), and U.S. patent No. 5,260,065.

In one variant of the invention, the liposomes are non-ionic. In one example, a liposome containing (a) dilaurate glycerol; (b) compounds with steroid skeleton contained in cholesterol; and (c) esters of fatty acids with the number of carbon atoms from about 12 to about 18. In another embodiment of the invention, the liposomes contain dilaurate glycerol, cholesterol, polyoxyethylene-10-stearyl ether and polyoxyethylene-9-lauric ether. In one of the embodiments of the invention these components are present in a ratio of about 38:12:33:17.

In one variant of the invention, the liposomes are present in therapeutic compositions for topical application in the amount calculated from the full volume of the composition, from about 10 mg/ml to about 100 mg/ml, for example, from about 15 mg/ml to about 50 mg/ml

Therapeutic compositions for topical application, useful from the point of view of the present invention may contain in addition to the above components, a variety of additional oil-soluble substance and/or water-soluble substances, Trad is traditionally used in compositions for application to the skin, hair and nails in amounts conventional in this field.

The drugs used in the framework of the present invention may also be present various other materials. These include adsorbents, moisturizers, proteins and polypeptides, preservatives and alkaline reagents. Examples of these reagents are described in the Handbook ICI Handbook, pp.1650-1667.

The composition forming the subject of the present invention may also contain chelating agents (such as EDTA), preservatives (e.g. parabens). Examples of appropriate preservatives and chelating agents are given on pages 1626 and 1654-55 Handbook ICI Handbook. In addition, therapeutic compositions for topical application, used in this invention can contain conventional cosmetic auxiliary substances, such as dyes, cloud emulsions (for example, titanium dioxide, pigments and flavors.

In another embodiment of the invention the active(s) component(s) included in the composition of the base cream or lotion, such as, for example, described in U.S. patent No. 6284234. The preferred embodiment of the invention includes (a) from about 1 percent to about 10 percent non-ionic lipid; (b) from about 75 percent to about 98 percent of the basic solution consisting of water or a mixture of water and hydrophilinae connection and the second basic solution, consisting of an alcohol, a polyhydric alcohol or mixtures thereof; and c) an effective amount of the active(s) component(s).

Application covering the composition

Covering the composition within the present invention can be applied in the form of sprayed fabric, Poperechnaya polymer or polymer that polymerizes or crosslinks after spraying. In one variant of the invention, the cover composition is a solution for application pump or spray, suspension or emulsion, which when coated on the skin forms a continuous or discontinuous coating, adhesive film or non-woven material. The sprayed fabric is described, for example, in the patent application U.S. 2005/0222320.

Covering the composition may further contain polymers that harden after deposition due to drying or under the action of UV radiation or slivaushiesia when present in contact with air, moisture, or slivaushiesia in contact with those present in air and oxygen. Examples include cyanacrylate, such as 2-octilinear, which rapidly polymerizes upon contact with airborne moisture.

In another embodiment of the invention covering the composition is sprayed from the tank with several, preferably two, compartments, in which separately stores the polymer and by whom the tender agent, and covering the composition in a known manner is formed by mixing a polymer and a crosslinking agent during spraying.

In one variant of the invention, the cover composition forms a porous coating for breathing of the skin. In one of these embodiments of the invention covering the composition comprises a mixture of porous particles with stitched polymer, where the porous particles embedded in the coating formed covering composition. The result is a more breathable coating due to the presence of porous particles, providing its permeability to air and moisture. In another embodiment of the invention covering the composition forms a microporous coating of micro bubbles that are present or formed in the cover composition after the distribution.

In one of the embodiments of the invention, the component(s)that provide(s) touch the reference point is(-BT) in the composition of the polymer-containing solution, suspension or emulsion, which, after distribution to form a rigid grid or holding the floor, sticking to the skin and solidified.

In one variant of the invention, the cover composition may contain an identifier that gives the composition of the view that distinguish it from therapeutic compositions for local p is imeneniya. This identifier can carry sensory information, that is, to give a composition smell or color different from the smell and color of therapeutic compositions for topical application. In one variant of the invention, the cover composition contains the identifier, such as a reflective flakes, colored micrograins or fibers, which give covering songs view that is different from therapeutic compositions for topical application.

In one variant of the invention, the cover composition is substantially covers therapeutic composition for topical use. In this document the expression "substantially covers" means that the coating or sheath caused by at least 75 percent, for example at least 90 percent; for example, at least 95 percent of the surface area applied to this therapeutic compositions for topical application. In another embodiment of the invention the covering composition covers at least 100% therapeutic compositions for topical application to the skin or fully covers therapeutic composition for topical application on the skin. In yet another embodiment of the invention the covering composition overlaps therapeutic composition for local application the Oia on the skin, outside the field of application of therapeutic composition for topical application, approximately evenly spread over the area of application of therapeutic composition for topical application in all directions, for example, covering the area with approximately 110% of the area of therapeutic compositions for topical application; for example, covering the area comprising approximately 150% of the area of application of therapeutic composition for topical use. In one variant of the invention, therapeutic composition and cover composition is applied in a circular motion, while covering composition overlaps therapeutic composition is at least 2 mm or at least about 5 mm, or at least about 10 mm

In one of the embodiments of the invention, a therapeutic composition for topical application covering the composition, or both components can minimize the possibility of flushing or are resistant to washout. Known composition having resistance to washout. For example, in published Patent application U.S. number 2005/0232876 describes the preparations for skin care, which can be used as a cosmetic, protective and therapeutic dermatological preparations, monsterously when applied to the skin smoothness and resistance to water. In the examples was measured by the contact angle of a water film formed by the compositions forming the subject of this invention, to demonstrate the water-resistant properties of these mixtures. The contact angle is measured by the index of wettability of the surface; it is described in the published Test Method ASTM D5725-99.

In one variant of the invention, the cover composition contains a non-toxic volatile solvent, evaporating of cover songs after distribution. Appropriate solvents are, in particular, ethanol, methanol and isopropanol.

In one of the embodiments of the invention, the patient wears a composition at least 1 hour or at least 2 hours, or at least 4 hours, or at least 8 hours.

The order of application

In one embodiment of the invention on the skin at first put essentially all therapeutic composition for topical application, and then on top of a therapeutic composition for topical application to the skin is applied essentially covering the entire composition.

In another embodiment of the invention and a therapeutic composition for topical application, and covering the composition is sprayed simultaneously on adjacent areas of the skin. Then nozzles move, increasing the coverage area so that arrivalsa composition was applied to the skin followed by a therapeutic composition for topical application and immediately blocked therapeutic composition for topical use. Spraying therapeutic compositions for topical application is terminated, while the coating covering the song continues to provide full coverage of the area of application of therapeutic composition for local application.

In both the above delivery methods each skin area consistently covered therapeutic composition for topical application, and then covering composition.

In one variant of the invention, therapeutic composition contains an additional crosslinking agent, under which the polymer covering composition cross-stitched in contact with therapeutic composition. To the appropriate cross-linking agents include, in particular, boric acid, glycerin, polyethylene glycol and monolaurin glycerin.

1. A delivery device for topical application, containing tank having a first chamber containing a therapeutic composition for topical application containing at least one active component; and a second chamber containing covering the composition; and the specified device delivery ensures consistent delivery of therapeutic compositions for topical application covering the composition on the skin of the patient, and the composition for local application and covering the compo is iciu metered through the valve and consistently delivered through a single nozzle.

2. The device according to claim 1, in which the active component provides a temporary analgesic effect when applied topically.

3. The device according to claim 1, in which the covering composition after distribution of the device forming the sprayed fabric or sprayed polymer.

4. The device according to claim 1, in which the active ingredient of a therapeutic composition for topical application selected from the group consisting of warming agents, cooling agents, analgesics, local action, revulsion means, means causing a feeling of warmth, substances that cause a cold feeling, and means causing a tingling sensation.

5. The device according to claim 1, in which the cover composition contains the identifier that distinguishes it from therapeutic compositions for topical application.

6. The device according to claim 1, in which the covering composition overlaps therapeutic composition for local application.

7. The device according to claim 6, in which the area covered by the covering composition, is approximately 110% of the area of therapeutic compositions for topical application.

8. The device according to claim 1, in which a therapeutic composition for topical application contains the first anesthetic active ingredient and the second active component against itching.

9. The device according to claim 1, in which the covering composition, the content of what it means to combat the itching.

10. The device according to claim 1, in which a therapeutic composition for topical application contains a crosslinking agent.

11. A delivery device for topical application, containing tank having a first chamber containing a therapeutic composition for topical application containing at least one active component; and a second chamber containing covering the composition; and the specified device delivery ensures consistent delivery of therapeutic compositions for topical application covering the composition on the skin of the patient, and therapeutic composition for topical application distributed from the device by pressing the first releasing button, and covering the composition distribute from the device by pressing the second releasing button.

12. The device according to claim 11, in which the active component provides a temporary analgesic effect when applied topically.

13. The device according to claim 11, in which the covering composition after distribution of the device forming the sprayed fabric or sprayed polymer.

14. The device according to claim 11, in which the active ingredient of a therapeutic composition for topical application selected from the group consisting of warming agents, cooling agents, analgesics, local action, revulsion means, means causing a feeling of warmth, with whom edst, causing a feeling of cold, and means causing a tingling sensation.

15. The device according to claim 11, in which the cover composition contains the identifier that distinguishes it from therapeutic compositions for topical application.

16. The device according to claim 11, in which the covering composition overlaps therapeutic composition for local application.

17. The device according to clause 16, in which the area covered by the covering composition, is approximately 110% of the area of therapeutic compositions for topical application.

18. The device according to claim 11, in which a therapeutic composition for topical application contains the first anesthetic active ingredient and the second active component against itching.

19. The device according to claim 11, in which the cover composition contains the remedy for itching.

20. The device according to claim 11, in which a therapeutic composition for topical application contains a crosslinking agent.

21. Device for local anesthetic therapy containing tank having a first chamber containing an anesthetic therapeutic composition for topical application containing at least one anesthetic active ingredient, and a second chamber containing covering the composition; and said device for local pain management provides a consistent assignment is of analgesic therapeutic compositions for topical application and covering composition, moreover, the composition for local application covering the composition is metered through the valve and consistently delivered through a single nozzle.

22. Device for local anesthetic therapy containing tank having a first chamber containing an anesthetic therapeutic composition for topical application containing at least one anesthetic active ingredient, and a second chamber containing covering the composition; and said device for local pain management ensures consistent distribution of analgesic therapeutic compositions for topical application and covering compositions, and therapeutic composition for topical application distributed from the device by pressing the first releasing button, and covering the composition distribute from the device by pressing the second releasing button.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to paediatric anaesthesiology, and may be used for executing the surgical operations of neck and head cancers in children. A pre-operative Kerdo index is determined. If observing an initial sympathicotonia, the anaesthesia is induced by sevoflurane inhalations and potentiated by administration of 1% propofol to be followed by sevoflurane inhalations.

EFFECT: method enables optimising the course of anaesthesia, achieving the normotonic sympathovagal balance and providing the haemodynamic stability by taking into account the individual vegetative response, as well as the separate and sequential administration of propofol and sevoflurane.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to anaesthesiology, and may be used as an anaesthesia care of a surgical intervention for carotid endaterectomy or internal carotid artery resection after pathological deformation thereof. That is ensured by general anaesthesia in a combination with deep and superficial cervical plexus blockade. Pre-medication is used the day before the operation and on the operative day in the morning. Diazepam is introduced intramuscularly 30 minutes before the operation in a combination with phentanyl; the introduction is followed by ECG monitoring and heart rate count, plethysmography with arterial blood saturation, non-invasive blood pressure measurement and neuromonitring according to a bispectral index or entropy. Catheterisation of patient's peripheral or central vein is followed by an infusion therapy, an ionotropic therapy, a cardiotropic therapy, peripheral resistance maintenance. If heart rate is no more than 80 beats per minute, the anaesthesia is induced to reach an anaesthetic depth according to the bispectral index or entropy within 40-60 units. Analgesia is provided by the intravenous introduction of 0.005% phentanyl; myoplegia is ensured by the intravenous introduction of a myorelaxant. After tracheal intubation, the patient is transferred to forced volumentic artificial pulmonary ventilation with the CO2 level within 35-45 mm Hg according to capnography. The anaesthesia is maintained by supplying an inhalation anaesthetic to the steam level of 0.8-1.0 MAK 0.8-0.9 litre of the air and oxygen flow containing 50% oxygen with controlling the inhalation anaesthetic volume by the level of the anaesthetic depth according to the bispectral index or entropy. That is followed by deep cervical plexus blockade. A tubercle of the VI cervical vertebra (a carotid tubercle) and a mastoid process are localised; thereafter a line connecting the above reference points is drawn on skin. The second line is drawn 1 cm below the first one in parallel. To verify an injection point of a local anaesthetic, the spines of IV, III, II cervical vertebras being at 1.5 cm from each other are palpated, and the reference point is the VI cervical vertebra. The needle is inserted perpendicularly to the skin and slightly in the caudal direction to reach the spines. The anaesthetic is introduced in a dose of 5-7 ml in each point C4, C3, C2. Another 5-7 ml of the anaesthetic is introduced in a point found in an apex of the mastoid process. The superficial cervical plexus blockade requires introducing he fan-shaped introduction of the anaesthetic solution in a dose of 15 ml in a point found in the middle of a lateral crus of the nodding muscle under the above muscle, 4-5 ml in each direction from the same point; the first and following injections are performed at a depth of a usual intramuscular needle perpendicularly to nodding muscle.

EFFECT: method provides the adequate and safe anaesthesia ensured by avoiding linear blood velocity reduction in the medial cerebral artery during the surgical intervention, preventing intracranial pressure increase, reducing cerebral perfusion pressure in a combination with providing adequate protection against surgical invasion with maintaining stroke volume and arterial pressure.

4 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely anaesthesia, and may be used as a postoperative anaesthesia accompanying low- and medium-injury operations. For this purpose, at the stages of anaesthetising and de-anaesthetising, nonsteroidal anti-inflammatory compounds (NSAICs) are introduced intravenously. The NSAIC dose is equivalent to ketorol 0.5-3.0 ml. The introduction is performed 1-3 times.

EFFECT: method provides the complete prevention of developing postoperative pain syndrome ensured by the intravenous introduction of the NSAIC at the specific stages of anaesthesia in certain doses.

1 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: presented group of inventions refers to anaesthesiology, and may be used in performing X-ray endovascular heart, aorta and other great vessel surgeries in infants and young children. For this purpose, 10-12 hours before the surgery, a patient is pre-medicated by administering benzodiazepine, antihistamine and blocker H2. The anaesthetic administration is enabled by fast induction of sevoflurane before the first surgical stage. Then, a two-flap laryngeal mask is used, its drainage duct is used to pass a gastric probe a correct placement of which is monitored by X-ray, and the gastric contents is evacuated. The probe is removed, and the same duct is used to insert an echocardiographic probe. The anaesthesia is maintained by infusion of propofol in a dose of 6-8 mg/kg/h and bolus introduction of an opioid analgesic. The artificial pulmonary ventilation is conducted through the laryngeal mask, and the patient is transferred to unassisted respiration with a dose of propofol to be reduced to 4-5 mg/kg/h. The principal stage of the surgery and ultrasonic control, or control with introducing a contrast agent, the echocardiographic probe is removed. Infusion of propofol is terminated after suturing and compression hemostasis. In the period of escaping the anaesthesia with the laryngopharyngeal reflexes recovered, air is evacuated from a cuff of the laryngeal mask, and after adequate respiration recovered, the same mask is removed.

EFFECT: group of inventions ensures the adequate anaesthesia in these patients by means of the developed method of lung ventilation using no myorelaxants, and prevented regurgitation of the gastric contents.

8 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, in particular to anesthesiology and intensive care, and may be used if preoperative preparation of the patients with chronic pancreatitis and manifested pain syndrome required. For this purpose, back skin of a sitting patient is treated within a puncture at the Th7-Th8 level. Then, an epidural space is punctured, and a puncture catheter needle is introduced therein, and the catheter is pushed forward in the cranial direction to a depth of 3 cm. The needle is removed, and the catheter is placed along the spine and is brought out to the subclavian region while strapped all over. Thereafter, a test dose of 2% lidocaine 3.0 ml is introduced. If observing no effects of spinal block, prolonged permanent introduction of 0.2% ropivacaine at rate 4-5 ml/hour 3 times a day. With underlying it, 30 minutes before a meal, fractional introduction of 0.75% ropivacaine 3.0 ml and 0.005% fentanyl 1.0 ml for 4-5 days is performed.

EFFECT: method provides the adequate preparation of the patients for pancreatic surgery due to pain relief that enables supplying proteins and eliminating hypovolemia, as well as due to improved pancreatic-duodenal microcirculation.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new derivatives of ((phenyl)imidazolyl)methylheteroaryl of formula wherein A represents pyridyl or thienyl having 0 or 1 substitute; B represents phenyl having 0, 1 or 2 substitutes; wherein each substitute independently represents alkyl having 1 to 8 carbon atoms, -F, -Cl, -Br or -CF3. Also, the invention refers to the use of the declared compounds for the purpose of preparing a therapeutic agent, a pharmaceutical composition on the basis of the declared compounds, and to a kit containing the pharmaceutical composition above.

EFFECT: there are prepared new derivatives of ((phenyl)imidazolyl)methylheteroaryl effective in pain management.

10 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, in particular, to experimental anesthesiology and resuscitation science. Method is realised in experiment by introduction of protamine sulfate in dose 10 mg/kg of animal weight before introduction of narcotic medication such as ether, or ethanol, or droperidol, or aminasin, or sodium oxybutirate.

EFFECT: invention makes it possible with introduction of narcotic medication to ensure short time of falling asleep of operated animal and long sleep during surgery.

2 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a new (-)-stereoisomer of formula (I) wherein X is H, or its pharmaceutically acceptable salt which agonise GABA receptor, to a pharmaceutical composition on the basis of the presented compound, to a method for preparing the (-)-stereoisomer of formula (I) or its pharmaceutically acceptable salt, to a method for inducing or maintaining general anaesthesia, to a method for promoting pain management and to a method for promoting pain management and to a method for prototyping antiemetic activity with the use of the presented (-)-stereoisomer or its pharmaceutically acceptable salt, as well as to a new diastereoisomer (-)-2,6-di-fluoro-butylphenyl ester of carbamic acid of formula (II) wherein R1 represents a chiral amino group, and X is H, or to its pharmaceutically acceptable salt.

EFFECT: preparing the pharmaceutically acceptable salt which agonise GABA receptor.

14 cl, 15 ex, 8 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a new (-)-stereoisomer of formula (I) wherein X is H, or its pharmaceutically acceptable salt which agonise GABA receptor, to a pharmaceutical composition on the basis of the presented compound, to a method for preparing the (-)-stereoisomer of formula (I) or its pharmaceutically acceptable salt, to a method for inducing or maintaining general anaesthesia, to a method for promoting pain management and to a method for promoting pain management and to a method for prototyping antiemetic activity with the use of the presented (-)-stereoisomer or its pharmaceutically acceptable salt, as well as to a new diastereoisomer (-)-2-fluoro-butyl-6-isopropylphenyl ester of carbamic acid of formula (II) wherein R1 represents a chiral amino group, and X is H.

EFFECT: preparing the pharmaceutically acceptable salt which agonise GABA receptor.

16 cl, 12 ex, 6 tbl, 4 dwg

FIELD: medicine.

SUBSTANCE: for the purpose of the anaesthetic therapy if indicated with the general anaesthesia of Sevorane and Fentanyl is combined with injecting 1% or 0.75% Naropin 5.0-25.0 ml in the beginning of the surgery in an introduction point of each Thoracoport. The surgery is followed by the non-narcotic analgesic anaesthesia if indicated.

EFFECT: invention provides preventing the postoperative pain syndrome, continuous postoperative maintenance of the anaesthesia and prevented developing chronic pain.

3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and is used for monitoring the effectiveness of the replacement renal therapy. The monitoring is implemented by the values of a coefficient of reduction RR and the Kt/V value. The concentration is measured by at least one waste product with the use of spectrophotometry in discharged fluid used for the replacement therapy. The discharged fluid circulates in a closed loop relatively to blood supplied from an apparatus for renal function replacement until a spectrophotometric value of the discharged fluid reaches the constant ABO. The coefficient RR or the Kt/V value is determined by equations RR = 1-AB(t)/ABO or Kt/V = -ln(AB(t)/ABO), wherein AB(t) is the spectrophotometric value of the discharged fluid used for the replacement renal therapy at the moment of time t of a procedure of the replacement therapy started after recirculation of the discharged fluid, K is an effective clearance of the waste product, V is a volume of distribution of the waste product, what is disclosed is an apparatus used for implementing the method and the apparatus for renal function replacement, the external blood circulation loop, a channel and valve system for conducting the replacement therapy and a measuring device.

EFFECT: invention provides adequacy control of the replacement renal therapy.

29 cl, 6 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment. A supply device comprises a pipeline of permeate and at least one concentrate pipeline for supply of permeate and dialysis concentrate (s) into a dialysis apparatus to be mixed to prepare a dialysis fluid, and also contains a waste water pipeline for waste water release from the dialysis apparatus. The waste water pipeline is substantially connected with a funnel-shaped release container wherein waste water free falls thereby encounters with an inclined section of a wall of the release container. The release container is formed by a funnel, an upper lid and a rotary door.

EFFECT: lower noise level, eliminated bad smell and higher sampling convenience.

9 cl, 8 dwg

FIELD: medicine.

SUBSTANCE: what is offered is a dialysis fluid regeneration system for blood purification system which comprises a number of devices. A device for dialysis fluid feed from a dialysis fluid and blood cell in a filtration manifold. The filtration manifold filters water from the dialysis fluid for producing the concentrated dialysis fluid. A device for discharge of a part of the concentrated dialysis fluid from the system. A device for one-line return of a non-discharged part of the concentrated dialysis fluid and water filtered from the dialysis fluid as a regenerated dialysis fluid into the dialysis fluid cell and/or into blood immediately. What is also offered is a method of dialysis fluid regeneration for the blood purification system after the dialysis fluid reacts with blood. Blood is supplied into the filtration device; the prepared filtrate representing water is returned into the dialysis fluid and blood cell, and the concentrated dialysis fluid liquid is supplied into the filtration device for discharge a part of the concentrated dialysis fluid from the system as the discharge fluid. The remained concentrated dialysis fluid is mixed with the filtrate prepared in the filtration device, and as the regenerated dialysis fluid is returned into the dialysis fluid and blood cell and/or into blood immediately.

EFFECT: invention enables continuous blood purification combined with the use of the small amount of the dialysis fluid in the loop with no fresh dialysis fluid added ensured by the developed regeneration system of the discharged fluid.

16 cl, 15 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in treating the patients with advanced and recurrent skin cancer. Substance of the method consists that the patient is exposed to the discrete gravity plasmapheresis; blood 400 ml is drawn once; prepared autoplasma is divided on two portions, each 150 ml whereto 30 ml of erythromass and 10 portions, each 10 ml. All the portions are collected in sterile containers and frozen at t =-24C. Then wide excision of a tumour nidus follows. Next day, erythrocyte-enriched autoplasma is incubated with cisplatin - 100 mg, methotrexate - 50 mg, bleomycine - 15 mg in a thermostat for 30 min at t=37C and introduced drop-by-drop intravenously. It is combined with intradermal paratumour immunotherapy with Lifeferon pre-incubated from one of the portions of the defrosted plasma 10 ml within 10 days.

EFFECT: use of the invention allows reducing risk of recurrent tumour following surgical excision of a primary tumour due to enabled direct immunomodulator delivery to the tumour nidus and its prolonged local action.

1 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to efferent treatment methods, and can be used for viral infection treatment. Therefor there are disclosed versions of method and an apparatus. The method includes blood or plasma sampling thereafter run through a porous hollow-filament membrane wherein lectin molecules are immobilised in a porous membrane exterior. The apparatus includes a processing chamber for blood or plasma sampling with contained lectin, and a porous membrane wherein blood or plasma cells cannot run through said membrane and contact with lectin.

EFFECT: inventions ensure effective isolating viral particles from blood or plasma due to substance molecules not being specifically affined to a target molecule, but contacting high-mannose viral glycoproteins or their fragments.

33 cl, 8 dwg, 10 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly gynecology and medical rehabilitation of adolescent girls with acute complicated salpingoophorite. It involves 3 plasmapheresis sessions with small plasma exfusion volume in addition to antibacterial therapy over a day interval in post-operation period. Immediately after each plasmapheresis session 2.2 ml of Mucosa compositum, 2.2 ml of Coenzyme compositum and 2.2 ml of Tonsilla compositum is administered intravenously. Injections are repeated after medical plasmapheresis course, the total of 10 injections over one day interval. In addition, Nux vomika-Homaccord, Gynacoheel, Traumel C are administered internally by 10 drops three times per day for one month starting from the first day of therapy.

EFFECT: complex detoxicative, anti-inflammatory, immune modulation effect allowing prevention of secondary mutations of central and peripheral hemodynamics, psychoemotional state, involuntary regulation and menstrual cycle disorders.

3 ex

FIELD: medical engineering.

SUBSTANCE: device has membrane, blood compartment for making blood/plasma circulate, hemodialysis compartment for making hemodialysis solution circulate. Blood/plasma compartment and hemodialysis compartment are separated. The first electrode is introduced into the cartridge placed directly in the blood/plasma compartment or in its inlet part. The second electrode is of opposite sign and placed directly in the hemodialysis compartment or in cartridge inlet part.

EFFECT: enhanced effectiveness in transferring molecules or substances from blood/plasma to hemodialysis solution composed according to patient requirements.

7 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention relates to a method for preparing concentrated acid component used in hydrocarbonate hemodialysis in carrying out the extracorporal blood treatment in treatment of patients with acute and chronic renal insufficiency. Method involves forming dry salts sets according to prescription. Salts are dissolved in purified water at room temperature followed by preparing concentrated acidic component for hydrocarbonate dialysis. Then prepared component is added to the device "Artificial kidney" wherein component is diluted. Prepared acidic component contains the following components, mole/l: sodium chloride (NaCl), 137.3-140.3; calcium chloride (CaCl2 x 6 H2O), 0.5-1.0; potassium chloride (KCl), 0.3-4.0; glucose, g/l, 1.0-5.0; sodium acetate, 0.3; citric acid (C6H8O7), 0.1-0.7; succinic acid (C4H6O4), 0.1-1.1. Invention provides simplifying method in preparing acidic component and composition of acidic component based on change of acetic acid for dry reagent - succinic acid and citric acid that shows positive effect on dynamic process in carrying out hemodialysis, decreases number of complications as acidosis that arise in adding significant amounts of acetate ions in body, reducing risk in transporting salt sets containing solution of concentrated acetic acid.

EFFECT: improved and simplified preparing method.

2 ex

FIELD: medicine.

SUBSTANCE: method involves extracorporally uniting immiscible recipient and patient blood flows in transfusion mode in direct and reverse immiscible flows, concurrently taking blood from recipient and patient veins. The blood flows are separated with semipermeable blood-filtering column membrane. The taken blood is returned later into recipient and patient veins.

EFFECT: enhanced effectiveness in restoring incretory relations in general organs and tissues metabolism balance.

3 cl, 2 tbl

FIELD: medicine, anesthesiology-resuscitation, neuropathology.

SUBSTANCE: it is necessary to carry out oxygenotherapy, intravenous injection of physiological solution and those of hydroxyethyl starch. Also, it is important to inject beta-blocators, heparin, opioids, alpha2-adrenoagonists, antagonists of NMDA-receptors, glucocorticoids, nimotope, actovegin. One should prescribe early enteral nutrition. On stabilizing the parameters of cardio-vascular and respiratory systems it is necessary to inject intravenously the solution of mildronate 10% - 10 ml for 10-14 d once daily and the intake of rheaferon-EC-lipint at the dosage of 10000-15000 U/kg or through a gastric probe for 5 d. The innovation enables to efficiently prevent pneumonia due to adequate immunotherapy of the above-mentioned pathology.

EFFECT: higher efficiency of prophylaxis.

3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and represents a self-degradable transdermal therapeutic system (TTS) containing at least one active ingredient, at least one agent disabling the active substance with the agent representing a solid substance or a paste, at least one release agent between the active substance and the agent disabling the active substance; the release agent represents a liquid-permeable and solid-impermeable layer, a mobile phase and at least one mechanical agent for perforating at least one adjacent layer of the TTS; the perforation agent has a dull outline and an acute or pointed area inside; when the TTS is released after the use, the perforation agent degrades the release agent between the release agent and the agent disabling the active ingredient thereby it enables the mobile phase supplied onto the agent disabling the active ingredient and enabling the contact of the active ingredient with the agent disabling the active ingredient, while the active ingredient is degraded by this contact.

EFFECT: device enables reducing a risk of undesired release of the preparation in transportation, provides the prolonged storage.

12 cl

Up!